Web of Science: 4 cites, Scopus: 5 cites, Google Scholar: cites,
Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation : phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
Giner Soriano, Maria (Universitat Autònoma de Barcelona)
Vedia Urgell, Cristina (Universitat Autònoma de Barcelona)
Roso Llorach, Albert (Universitat Autònoma de Barcelona)
Morros, Rosa (Universitat Autònoma de Barcelona)
Capellà, Dolors (Universitat de Girona. Departament de Ciències Mèdiques)
Castells, Xavier (Universitat de Girona. Departament de Ciències Mèdiques)
Ferreira González, Ignacio (Hospital Universitari Vall d'Hebron)
Troncoso Mariño, Amelia (Hospital Universitari Vall d'Hebron. Servei de Farmacologia)
Diògene, Eduard (Hospital Universitari Vall d'Hebron. Servei de Farmacologia)
Elorza, Josep Mª (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Casajuana, Marc (Universitat Autònoma de Barcelona)
Bolíbar, Bonaventura (Universitat Autònoma de Barcelona)
Violan, Concepció (Universitat Autònoma de Barcelona)

Data: 2016
Resum: Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Safety and Costs in Atrial Fibrillation (ESC-FA) study is to analyse the drugs used for the management of the disease in real-use conditions, particularly the antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of phase I of the ESC-FA study and the baseline characteristics of newly diagnosed patients with atrial fibrillation in Catalonia, Spain. The data source is System for the Improvement of Research in Primary Care (SIDIAP) database. The population included are all patients with non-valvular atrial fibrillation diagnosis registered in the electronic health records during 2007–2012. A total of 22 585 patients with non-valvular atrial fibrillation were included in the baseline description. Their mean age was 72. 8 years and 51. 6% were men. The most commonly prescribed antithrombotics were vitamin K antagonists (40. 1% of patients) and platelet aggregation inhibitors (32. 9%); 25. 3% had not been prescribed antithrombotic treatment. Age, gender, comorbidities and co-medication at baseline were similar to those reported for previous studies. The next phase in the ESC-FA study will involve assessing the effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes' rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation.
Nota: Número d'acord de subvenció MSSSI/EC11–251
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Matèria: Atrial fibrillation ; Electronic health records ; Platelet aggregation inhibitors
Publicat a: BMJ open, Vol. 6, issue 1 (Jan. 2016) , art. e010144, ISSN 2044-6055

PMID: 26823179
DOI: 10.1136/bmjopen-2015-010144


11 p, 1.4 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-02-07, darrera modificació el 2019-09-27



   Favorit i Compartir